Rezultati pretraživanja
  1. prije 19 minuta
  2. prije 2 sata

    Happy to support this case! Kempen acted as co-manager in the $154m capital raise of DBV Technologies -

  3. : New SEC Filing for DBVT: Form 6-K (No. 0001193125-20-024346):

  4. prije 20 sati

    NICE AND GREEN TODAY --JUST CRUSHED THROUGH $1.40 RESISTANCE SEE YA AT $1.74 SOON💵💵💵💵💵💵

  5. 4. velj

    has 1st Peanut Allergy Drug but not the last - have a Breakthrough Designation in General Food Allergy for Xolair (Omalizumab) already Approved in asthma-top line data in 8 mos in Severe drug allergies. Many refer to as only competition - isn’t so.

    Prikaži ovu nit
  6. 3. velj

    This one getting ready to make a move out of trips. Call the company they are excited for what's ahead $$

  7. 2. velj

    Aimmune shares already reflect 'significant' launch optimism, says Stifel

  8. 2. velj
    Odgovor korisnicima

    Very likely will flunk adcom, it is safer because there is no efficacy. They also failed P3

  9. 30. sij
  10. 30. sij

    gave a nice and fast 2-1 scalp

  11. 30. sij
  12. 30. sij

    , , , and today. Here are the chart guys, barely made it out green, was going for a 1:1 on that play, point stop. started pushing upwards; and saw an entry for long.

  13. 30. sij

    I take what market gives - thanks

  14. 30. sij
  15. 29. sij
  16. 29. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.